Juan Fortea

Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia.

Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia.

Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis.

Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain.

Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation.

Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation.

Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.

TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes.

Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion.

Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami.

Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study.

Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain.

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.

Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?

Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.

Patterns of Performance on the Modified Cued Recall Test in Spanish Adults With Down Syndrome With and Without Dementia.

Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.

Assessing the role of TUBA4A gene in frontotemporal degeneration.

Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome.

Longitudinal brain structural changes in preclinical Alzheimer's disease.

CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.

Prevention of dementia, an immediate challenge.

A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk.

Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum.

Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET.

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.

Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease.

Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.

Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.

CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies.

The pitfalls of biomarker-based classification schemes.

Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the expansion mutation.

Cortical microstructural changes along the Alzheimer's disease continuum.

Synaptic phosphorylated α-synuclein in dementia with Lewy bodies.

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease.

Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease.

The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease.

The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Challenges associated with biomarker-based classification systems for Alzheimer's disease.

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease.

CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.

Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.

Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.

Nanoscale structure of amyloid-β plaques in Alzheimer's disease.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

Exosome release and cargo in Down syndrome.

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review.

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors.

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?

APP-derived peptides reflect neurodegeneration in frontotemporal dementia.

Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease.

Further understanding the connection between Alzheimer's disease and Down syndrome.

COVID-19-associated ophthalmoparesis and hypothalamic involvement.

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis.

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly.

Evaluation of biochemical and hematological parameters in adults with Down syndrome.

Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum.

Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease.

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.

White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.

Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture.

Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve.

Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia.

Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration.

AMYQ: An index to standardize quantitative amyloid load across PET tracers.

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity.

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.

Opportunities, barriers, and recommendations in down syndrome research.

Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis.

Sleep Disorders in Adults with Down Syndrome.

Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.

Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome.

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients.

Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults.

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.

Alzheimer's disease associated with Down syndrome: a genetic form of dementia.

Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia.

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone.

Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders.

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.

Cortical microstructure in primary progressive aphasia: a multicenter study.

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.

Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group.

New insights into the genetic etiology of Alzheimer's disease and related dementias.

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease.

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications.

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.

Myelin loss in C9orf72 hexanucleotide expansion carriers.

Network Tau spreading is vulnerable to the expression gradients of and glutamatergic-related genes.